» Articles » PMID: 38123863

Liposome-Mediated Anti-Viral Drug Delivery Across Blood-Brain Barrier: Can Lipid Droplet Target Be Game Changers?

Overview
Publisher Springer
Date 2023 Dec 20
PMID 38123863
Authors
Affiliations
Soon will be listed here.
Abstract

Lipid droplets (LDs) are subcellular organelles secreted from the endoplasmic reticulum (ER) that play a major role in lipid homeostasis. Recent research elucidates additional roles of LDs in cellular bioenergetics and innate immunity. LDs activate signaling cascades for interferon response and secretion of pro-inflammatory cytokines. Since balanced lipid homeostasis is critical for neuronal health, LDs play a crucial role in neurodegenerative diseases. RNA viruses enhance the secretion of LDs to support various phases of their life cycle in neurons which further leads to neurodegeneration. Targeting the excess LD formation in the brain could give us a new arsenal of antiviral therapeutics against neuroviruses. Liposomes are a suitable drug delivery system that could be used for drug delivery in the brain by crossing the Blood-Brain Barrier. Utilizing this, various pharmacological inhibitors and non-coding RNAs can be delivered that could inhibit the biogenesis of LDs or reduce their sizes, reversing the excess lipid-related imbalance in neurons. Liposome-Mediated Antiviral Drug Delivery Across Blood-Brain Barrier. Developing effective antiviral drug is challenging and it doubles against neuroviruses that needs delivery across the Blood-Brain Barrier (BBB). Lipid Droplets (LDs) are interesting targets for developing antivirals, hence targeting LD formation by drugs delivered using Liposomes can be game changers.

Citing Articles

Tailored Intranasal Albumin Caged Selegiline-α Synuclein siRNA Liposome with Improved Efficiency in Parkinson's Model.

Katamesh A, Abdel-Bar H, Break M, Hassoun S, Subaiea G, Radwan A Pharmaceutics. 2025; 17(2).

PMID: 40006609 PMC: 11859980. DOI: 10.3390/pharmaceutics17020243.


Encapsulation of paclitaxel into date palm lipid droplets for enhanced brain cancer therapy.

Yousfan A, Moursel N, Hanano A Sci Rep. 2024; 14(1):32057.

PMID: 39738802 PMC: 11685383. DOI: 10.1038/s41598-024-83715-7.


In Vitro and In Vivo Evaluation of Lactoferrin-Modified Liposomal Etomidate with Enhanced Brain-Targeting Effect for General Anesthesia.

Wu A, Shi H, Yang L, Zhang H, Nan X, Zhang D Pharmaceutics. 2024; 16(6).

PMID: 38931926 PMC: 11207770. DOI: 10.3390/pharmaceutics16060805.

References
1.
Langner M, Kral T . Liposome-based drug delivery systems. Pol J Pharmacol. 1999; 51(3):211-22. View

2.
Chung J, Wu X, Lambert T, Lai Z, Walther T, Farese Jr R . LDAF1 and Seipin Form a Lipid Droplet Assembly Complex. Dev Cell. 2019; 51(5):551-563.e7. PMC: 7235935. DOI: 10.1016/j.devcel.2019.10.006. View

3.
Estes R, Lin B, Khera A, Davis M . Lipid Metabolism Influence on Neurodegenerative Disease Progression: Is the Vehicle as Important as the Cargo?. Front Mol Neurosci. 2022; 14:788695. PMC: 8721228. DOI: 10.3389/fnmol.2021.788695. View

4.
Lim Kee Chang W, Chan T, Raguseo F, Mishra A, Chattenton D, T M de Rosales R . Rapid short-pulses of focused ultrasound and microbubbles deliver a range of agent sizes to the brain. Sci Rep. 2023; 13(1):6963. PMC: 10147927. DOI: 10.1038/s41598-023-33671-5. View

5.
Milla P, Dosio F, Cattel L . PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab. 2011; 13(1):105-19. DOI: 10.2174/138920012798356934. View